Clinical efficacy of chloroquine diphosphate in the treatment of discoid lupus erythematosus

Authors

  • Yulia Pimenova Corresponding author

DOI:

https://doi.org/10.66344/jpad.32.1.2022.1834

Abstract

Discoid lupus erythematosus (DLE) is the most common clinical type of chronic cutaneous Lupus erythematosus (СLE). In the absence of a timely diagnosis and treatment, it may cause scarring and skin atrophy. The aim of the treatment is a fast and efficient reduction of the inflammatory process. We present a case of a DLE patient who was successfully treated with chloroquine diphosphate (CD). A 25-year-old woman presented with ruby-red plaques over the face, forehead, nose, cheeks, chin that merged into a butterfly-shaped rash around the nose and zygomatic arches. Treatment with СD (250 mg twice a day for two months) resulted rapidly effective with persistent efficacy and led to the almost complete clearance of cutaneous lesions. However, the treatment was discontinued due to visual disturbances.

Downloads

Published

2022-03-29

How to Cite

1.
Pimenova Y. Clinical efficacy of chloroquine diphosphate in the treatment of discoid lupus erythematosus. J Pak Assoc Dermatol [Internet]. 2022Mar.29 [cited 2026Apr.12];32(1):203-5. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/1834

Issue

Vol. 32 No. 1 (2022): January - March

Section

Case Reports

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.